This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ischia, R. Articles by Winkler, H. Search for Related Content PubMed PubMed Citation Articles by Ischia, R. Articles by Winkler, H.

Levels and Molecular Properties of Secretoneurin-Immunoreactivity in the Serum and Urine of Control and Neuroendocrine Tumor Patients¹

Departments of Pharmacology (R.I., R.F.-C., U.E., P.L.-S., A.L., H.W.) and Internal Medicine (R.W.G., G.F.), University of Innsbruck, A-6020 Innsbruck, Austria; Department of Biomedical Science and Human Oncology, University of Torino (A.P.), 10126 Torino, Italy; and Department of Pharmacology, School of Pharmacy, Central University of Venezuela (L.Z.C.), Caracas 1041 A, Venezuela.

Address correspondence and requests for reprints to: R. Fischer-Colbrie, Department of Pharmacology, University of Innsbruck, Peter-Mayr-Str. 1a, A-6020 Innsbruck, Austria. E-mail: fischer-colbrie{at}uibk.ac.at

We have determined the levels of secretoneurin (SN), a novel 33-amino acid neuropeptide belonging to the class of chromogranins, in the serum and urine of healthy subjects and patients suffering from various tumors. SN serum levels averaged 22.1 ± 1.1 fmol/mL. They were 5-fold higher in younger children and then declined continuously. SN levels were positively correlated with serum creatinine, suggesting an influence of renal function on the clearance of SN from the serum. In the urine 80.0 fmol/mL SN was present.

In patients with endocrine tumors like gut carcinoids, endocrine pancreatic tumors, oat cell lung carcinomas, and pheochromocytomas, SN serum levels were elevated up to 45-fold. Patients suffering from neuroblastomas, insulinomas, pituitary adenomas including acromegaly, and solid nonendocrine tumors had concentrations in the normal range.

In human serum, SN-immunoreactivity was confined to the free peptide SN; neither larger intermediate-sized forms nor the precursor secretogranin II were detected. An efficient removal of the small molecule SN from the serum by the kidney explains why SN serum levels are lower when compared to chromogranin A, which is present as large molecule in serum.

This article has been cited by other articles:

				R. Kirchmair, M. Egger, D. H. Walter, W. Eisterer, A. Niederwanger, E. Woell, M. Nagl, M. Pedrini, T. Murayama, S. Frauscher, et al. Secretoneurin, an Angiogenic Neuropeptide, Induces Postnatal Vasculogenesis Circulation, August 31, 2004; 110(9): 1121 - 1127. [Abstract] [Full Text] [PDF]

				L. Yon, J. Guillemot, M. Montero-Hadjadje, L. Grumolato, J. Leprince, H. Lefebvre, V. Contesse, P.-F. Plouin, H. Vaudry, and Y. Anouar Identification of the Secretogranin II-Derived Peptide EM66 in Pheochromocytomas as a Potential Marker for Discriminating Benign Versus Malignant Tumors J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2579 - 2585. [Abstract] [Full Text] [PDF]

				L. Taupenot, K. L. Harper, and D. T. O'Connor The Chromogranin-Secretogranin Family N. Engl. J. Med., March 20, 2003; 348(12): 1134 - 1149. [Full Text] [PDF]